Sep 2026· International Journal of Neuropsychopharmacology· Vol 29, pp. i248 - i248· 0 citations
TL;DR
This session will provide a comprehensive overview of the translational, preclinical, and early clinical research, including key methodological considerations, that has helped to propel zatolmilast into a registrational, Phase 2/3 clinical development program in FXS.
Abstract
Abstract Background Drug development in Fragile X syndrome (FXS) has been challenging with multiple development programs failing to achieve positive pivotal study results over decades of continued effort. Meanwhile translational research has continued to lead to the identification of clinically relevant biological pathways within FXS and subsequently the discovery of new investigational therapies. Aims & Objectives This presentation will describe the scientific trajectory that led to the development of zatolmilast, a negative allosteric PDE4D inhibitor, as an investigational treatment for FXS Method Review of preclinical and clinical research. Results Through collaboration among patient advocacy, FXS researchers, and the pharmaceutical industry, preclinical studies have informed early clinical testing and a positive proof of concept study ultimately led to the initiation of a registrational clinical development program aimed at delivering the first targeted FXS treatment to the community. Phase 2/3 study results are forthcoming. Discussion & Conclusions This session will provide a comprehensive overview of the translational, preclinical, and early clinical research, including key methodological considerations, that has helped to propel zatolmilast into a registrational, Phase 2/3 clinical development program in FXS. By sharing both the experience and learnings from this foundational work, we aspire to inform future interventional clinical trials in FXS.
This review provides a structured overview of biologics and natural products in the ALS clinical pipeline, with particular emphasis on candidates that entered, advanced through, or completed clinical evaluation between 2022 and the end of 2025.
C. Huang, C. Sanchez-Santos, L. Martínez-González et al.· Expert Opinion on Investigat...· 0 citations
Abstract Background There is a critical need to change the treatment paradigm for mental disorders by developing interventions that are able to target specific clinical components, alter the disease course and are not merely palliative in intent. A key strategy towards this goal is to focus research on causal pathways...
S. Sundram· International Journal of Neu...· 0 citations
BACKGROUND
Tau pathology is strongly associated with neurodegeneration and clinical progression in Alzheimer's disease (AD), positioning it as an important therapeutic target. However, tau-targeted therapies have thus far demonstrated limited and inconsistent translation into meaningful clinical benefit.
OBJECTIVE
To...
Ling Yin, Ruo-Di Ren, Christopher Leo et al.· Pharmacological Research· 0 citations
Abstract Background Dementia currently affects some 57.4 million people worldwide and approximately 99% of patients with Alzheimer’s Disease (AD) exhibit neuropsychiatric symptoms (NPS). Agitation is a particularly resistant clinical burden characterized by verbal and physical aggression that compromises safety. Author...
D. Scuteri, M. Contrada, K. Hamamura et al.· International Journal of Neu...· 0 citations
Neuropsychiatric and neurodegenerative disorders show wide variability in treatment response, thus limiting the effectiveness of traditional symptom-based neuropharmacology. Precision medicine offers a more targeted approach by combining pharmacogenomics, multi-omics data, and artificial intelligence to guide individua...
L. al-Eitan· Current Neuropharmacology· 0 citations
Parkinson's disease (PD) is a growing public health problem and biologically targeted therapeutics (BTTs) that slow disease progression are urgently needed. However, the development of effective BTTs is challenging as PD is a clinically defined syndrome with pathobiological heterogeneity and the pathobiological process...
R. Schneider, G. Skibinski, B. Fiske et al.· Journal of Parkinson's Disea...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.